There are two types of antithrombin defeciencies, namely, type I and type II. Inadequate amount of antithrombin is called type I and type II is associated with normal levels of antithrombin but reduced activity levels in case of affected patients blood. Blood clotting is associated with symptoms such as fainting, swollen legs or feet, increased heart rate, shortness of breath, among others. Antithrombin defenciency could either be acquired or inherited. Inherited antithrombin defeciency is a rare occurrence and only a maximum of 0.2% of the population has it. One of the most popular drugs for treatment of antithrombin defeciency available on the market is ATryn, developed by rEVO Biologics and received the FDA approval in 2009.
In terms of applications, the Antithrombin market has been segmented across the following:
Monoclonal and Polyclonal antibodies
Asia Pacific is expected to exhibit the highest growth rate in the antrithrombin market throughout the forecast period considered in this report. This is attributed to the increasing popualtion in this region. However, in terms of market share, North America and Europe account for the largest share and will maintain this position till the end of the forecast period.
The market has been segmented based on the following geographies:
A significant amount of consolidation has been taking placed in the global antithrombin market.
Following are just a few of the companies that are operating in the Antithrombin market:
Thermo Fisher Scientific Inc
American Diagnostica GmbH
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Antithrombin Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis
4. Antithrombin Market Forces
4.1. Market Drivers
4.2. Market Constraints
4.3. Market Challenges
4.4. Attractiveness of the Antithrombin Market
4.4.1. Power of Suppliers
4.4.2. Power of Customers
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitution
4.4.5. Degree of Competition
5. Antithrombin Market - Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Antithrombin Market By Application
6.1. Dry Chemistry
6.4. Monoclonal and Polyclonal antibodies
6.5. Chromogenic Substrates
6.6. DNA Probes
6.10. Artificial Intelligence
7. Antithrombin Market By Geography
7.2. Global Study
7.3.1. North America
8. Antithrombin Market Entropy
8.1. New Product Launches
8.2. M&As, Collaborations, JVs and Partnerships
9. Company Profiles
9.1. Abbott Laboratories
9.2. Thermo Fisher Scientific Inc.
9.3. Siemens AG
9.4. Dickinson and Company
9.5. Sysmex Corporation
9.6. Trinity Biotech Plc
9.8. Beckman Coulter Inc.
9.9. American Diagnostica GmbH
9.10. Axis-Shield Plc
9.11. Ovation Pharmaceuticals Inc.
9.12. rEVO Biologics
"*Financials would be provided on a best efforts basis for private companies"
10.3. Research Methodology
10.5. Compilation of Expert Insights